search
Back to results

Does Concurrent Hydrocortisone With Venlafaxine XR Speed Antidepressant Response?

Primary Purpose

Depressive Disorder, Major

Status
Completed
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
venlafaxine XR
hydrocortisone
Sponsored by
Stanford University
About
Eligibility
Locations
Outcomes
Full info

About this trial

This is an interventional treatment trial for Depressive Disorder, Major

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria::- outpatients at least 18 years of age current major depressive episode HDRS greater than or equal to 21 good physical health Exclusion Criteria:- history of sensitivity, intolerance, or non-response to venlafaxine history of sensitivity to hydrocortisone history of bipolar 1 illness meets DSM-IV criteria for a current or past psychotic disorder meets DSM-IV criteria for substance abuse or dependence in previous 6 months significant imminent suicide risk medical condition that would compromise participation in the study woman of child bearing potential not using adequate birth control in the opinion of the investigator

Sites / Locations

  • Stanford University School of Medicine

Outcomes

Primary Outcome Measures

To determine if treatment of major depression with hydrocortisone concurrent with starting venlafaxine XR speeds onset of antidepressant action.

Secondary Outcome Measures

To determine if hydrocortisone pre-treatment augments venlafaxine XR response.

Full Information

First Posted
September 13, 2005
Last Updated
October 2, 2019
Sponsor
Stanford University
Collaborators
Wyeth is now a wholly owned subsidiary of Pfizer
search

1. Study Identification

Unique Protocol Identification Number
NCT00186264
Brief Title
Does Concurrent Hydrocortisone With Venlafaxine XR Speed Antidepressant Response?
Official Title
Does Concurrent Hydrocortisone With Venlafaxine XR Speed Antidepressant Response?
Study Type
Interventional

2. Study Status

Record Verification Date
October 2019
Overall Recruitment Status
Completed
Study Start Date
August 2002 (Actual)
Primary Completion Date
April 2006 (Actual)
Study Completion Date
April 2006 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Stanford University
Collaborators
Wyeth is now a wholly owned subsidiary of Pfizer

4. Oversight

5. Study Description

Brief Summary
The primary purpose of this study is to examine whether IV hydrocortisone can speed up the time required for Venlafaxine XR to work.
Detailed Description
Participants will be treated with Venlafaxine XR for 6 weeks. The dose of Venlafaxine XR will begin at 37.5 mg/day and be gradually increased to a maximum of 225 mg/day. The dose may be kept as low as 75 mg/day if necessary. Study doctor will be assessing mood to determine if some patients respond more quickly than the several weeks often required for an antidepressant to begin working. On the first day of treatment with Venlafaxine XR, participant will be randomly assigned (similar to a flip of a coin) to receive hydrocortisone 15 mg /day or placebo for two days. Placebo is an inactive substance, like a sugar pill. This dose of hydrocortisone is less than a typical replacement dose for patients who are not producing cortisol (hydrocortisone) naturally. The hydrocortisone is administered intravenously (in a vein) over the course of 2 hours for two consecutive days. Neither participant nor study doctor will know which treatment participant is receiving. However, this information is available to study doctor if it is needed.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Depressive Disorder, Major

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
Double
Allocation
Randomized
Enrollment
18 (Actual)

8. Arms, Groups, and Interventions

Intervention Type
Drug
Intervention Name(s)
venlafaxine XR
Intervention Type
Drug
Intervention Name(s)
hydrocortisone
Primary Outcome Measure Information:
Title
To determine if treatment of major depression with hydrocortisone concurrent with starting venlafaxine XR speeds onset of antidepressant action.
Secondary Outcome Measure Information:
Title
To determine if hydrocortisone pre-treatment augments venlafaxine XR response.

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria::- outpatients at least 18 years of age current major depressive episode HDRS greater than or equal to 21 good physical health Exclusion Criteria:- history of sensitivity, intolerance, or non-response to venlafaxine history of sensitivity to hydrocortisone history of bipolar 1 illness meets DSM-IV criteria for a current or past psychotic disorder meets DSM-IV criteria for substance abuse or dependence in previous 6 months significant imminent suicide risk medical condition that would compromise participation in the study woman of child bearing potential not using adequate birth control in the opinion of the investigator
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Charles DeBattista
Organizational Affiliation
Stanford University
Official's Role
Principal Investigator
Facility Information:
Facility Name
Stanford University School of Medicine
City
Stanford
State/Province
California
ZIP/Postal Code
94305
Country
United States

12. IPD Sharing Statement

Learn more about this trial

Does Concurrent Hydrocortisone With Venlafaxine XR Speed Antidepressant Response?

We'll reach out to this number within 24 hrs